We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
-2.52%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$196M
AUM Growth
-$77.5M
Cap. Flow
-$72.9M
Cap. Flow %
-37.24%
Top 10 Hldgs %
56.4%
Holding
63
New
21
Increased
5
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.1M
2
MDT icon
Medtronic
MDT
+$6.07M
3
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$4.21M
4
ABT icon
Abbott
ABT
+$4.16M
5
CAH icon
Cardinal Health
CAH
+$2.85M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$12.9M
2
SHPG
Shire pic
SHPG
+$10.9M
3
LLY icon
Eli Lilly
LLY
+$10.1M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.65M
5
AGN
Allergan plc
AGN
+$9.63M

Sector Composition

Rank Sector Weight
1 Healthcare 60.02%
2 Industrials 1.3%
3 Consumer Discretionary 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$17.1B
$2.69M 1.37%
202,520
+15,300
+8% +$236K
FOMX
27
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.57M 1.31%
405,374
-167,254
-29% -$1.11M
TNET icon
28
TriNet
TNET
$2.74B
$2.55M 1.3%
122,563
-191,112
-61% -$3.5M
FWP
29
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.26M 1.16%
17,782
-13,133
-42% -$1.77M
DMK
30
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$1.92M 0.98%
9,778
-8,255
-46% -$3.81M
MCK icon
31
McKesson
MCK
$98.5B
$1.87M 0.95%
10,000
-73,600
-88% -$12.9M
IQV icon
32
IQVIA
IQV
$34.4B
$1.86M 0.95%
+28,541
New +$1.91M
SAGE
33
PUT
DELISTED
Sage Therapeutics
SAGE
$1.71M 0.87%
+56,800
New +$1.89M
AFAM
34
DELISTED
Almost Family Inc
AFAM
$1.21M 0.62%
+28,452
New +$1.17M
ADMS
35
DELISTED
Adamas Pharmaceuticals
ADMS
$855K 0.44%
56,500
+36,500
+183% +$602K
MTEM
36
DELISTED
Molecular Templates, Inc.
MTEM
$847K 0.43%
8,082
-15,871
-66% -$1.14M
VKTX icon
37
Viking Therapeutics
VKTX
$4.31B
$699K 0.36%
+554,382
New +$731K
SYRE icon
38
Spyre Therapeutics
SYRE
$8.7B
$690K 0.35%
+5,675
New +$1.09M
OASM
39
DELISTED
Oasmia Pharmaceutical AB
OASM
$424K 0.22%
123,000
– –
PFNX
40
DELISTED
Pfenex Inc.
PFNX
$411K 0.21%
49,092
-614,084
-93% -$4.96M
TEAR
41
DELISTED
TearLab Corporation
TEAR
$407K 0.21%
+63,544
New +$465K
PETX
42
DELISTED
Aratana Therapeutics, Inc.
PETX
$378K 0.19%
+59,869
New +$385K
IMNP
43
DELISTED
Immune Pharmaceuticals Inc.
IMNP
$79K 0.04%
9,883
– –
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-153,778
Closed -$9.65M
EDIT icon
45
Editas Medicine
EDIT
$457M
– –
-7,714
Closed -$266K
JAZZ icon
46
PUT
Jazz Pharmaceuticals
JAZZ
$15.5B
– –
-247,400
Closed -$32.3M
LLY icon
47
Eli Lilly
LLY
$1.05T
– –
-140,392
Closed -$10.1M
LNTH icon
48
Lantheus
LNTH
$7B
– –
-446,098
Closed -$843K
NSPR icon
49
InspireMD
NSPR
$32.9M
– –
0
– -$4K
NVS icon
50
Novartis
NVS
$293B
– –
-106,007
Closed -$6.88M
1
2
3

Similar funds

AWC
Abundance Wealth Counselors State College, Pennsylvania $697M AUM 23.83% 1-Year Est. Return
AIA
Allied Investment Advisors Billings, Montana $697M AUM 21.33% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
FCM
Fourpath Capital Management Oklahoma City, Oklahoma $697M AUM 29.98% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
CA
Cortland Associates St Louis, Missouri $697M AUM 4.23% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return

Sio Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sio Capital Management held 63 positions worth $196M, down 28% from $273M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sio Capital Management withdrew a net $72.9M in Q2 2016, closing 19 positions and reducing 15 holdings. Its most notable exit was Shire pic, an estimated $10.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 74% a quarter earlier, followed by Industrials and Consumer Discretionary.

Against the trend, Sio Capital Management opened a new position in Biogen worth $14.8M.

  • Sio Capital Management's largest Q2 2016 buy was Biogen: 61,000 shares worth $14.8M.
  • Sio Capital Management added most to Cardinal Health in Q2 2016, an estimated $2.85M increase.
  • Sio Capital Management's biggest Q2 2016 reduction was McKesson, cutting an estimated $12.9M.
  • Sio Capital Management fully exited Shire pic in Q2 2016, selling an estimated $10.9M.
  • Sio Capital Management's ten largest holdings make up 56% of its $196M portfolio in Q2 2016.
  • Sio Capital Management opened 21 new positions and closed 19 in Q2 2016.
  • Sio Capital Management's portfolio value fell 28% quarter-over-quarter to $196M.

Based on Sio Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.